Using targeted immune cells to treat brain lymphoma
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma
This study is testing a new way to treat primary central nervous system lymphoma by delivering special immune cells directly into the brain to help them better fight the cancer, and it's designed for patients looking for more effective options than what's currently available.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10912468 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating primary central nervous system lymphoma (PCNSL) by administering CD19-targeting chimeric antigen receptor (CAR) T cells directly into the brain's ventricles. The goal is to enhance the effectiveness of these immune cells in attacking lymphoma cells that are difficult to reach with traditional intravenous methods. By focusing on locoregional delivery, the study aims to improve patient outcomes compared to existing treatments that have not changed in decades. Patients will be monitored for safety and efficacy as the treatment progresses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with primary central nervous system lymphoma who have not responded adequately to standard treatments.
Not a fit: Patients with other types of lymphoma or those who do not have central nervous system involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with primary central nervous system lymphoma, potentially leading to better survival rates.
How similar studies have performed: Previous studies have shown success with locoregional delivery of CAR T cells in treating other central nervous system malignancies, suggesting a promising avenue for this approach.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Wang, Xiuli — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Xiuli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.